[go: up one dir, main page]

CO2018003759A2 - Tratamiento de la neuropatía periférica diabética usando células placentarias - Google Patents

Tratamiento de la neuropatía periférica diabética usando células placentarias

Info

Publication number
CO2018003759A2
CO2018003759A2 CONC2018/0003759A CO2018003759A CO2018003759A2 CO 2018003759 A2 CO2018003759 A2 CO 2018003759A2 CO 2018003759 A CO2018003759 A CO 2018003759A CO 2018003759 A2 CO2018003759 A2 CO 2018003759A2
Authority
CO
Colombia
Prior art keywords
treatment
diabetic peripheral
peripheral neuropathy
placental cells
cells
Prior art date
Application number
CONC2018/0003759A
Other languages
English (en)
Inventor
Steven A Fischkoff
Denesh Chitkara
Original Assignee
Celularity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celularity Inc filed Critical Celularity Inc
Publication of CO2018003759A2 publication Critical patent/CO2018003759A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/50Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan en la presente métodos de uso de células placentarias adherentes a plástico de cultivo tisular CD10+, CD34- , CD105+, CD200+, ej., células madre placentarias, en el tratamiento de la neuropatía periférica diabética (DPN). El método proporcionado comprende administrar a un sujeto una composición que comprende células madre placentarias CD10+, CD34-, CD105+, CD200+. También se proporciona en la invención una población de células que comprende células placentarias adherentes a plástico de cultivo tisular CD10+, CD34-, CD105+, CD200+, por ejemplo, células madre placentarias, para uso en la fabricación de un medicamento para el tratamiento de la neuropatía periférica diabética.
CONC2018/0003759A 2015-09-15 2018-04-09 Tratamiento de la neuropatía periférica diabética usando células placentarias CO2018003759A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562218885P 2015-09-15 2015-09-15
PCT/US2016/051571 WO2017048741A1 (en) 2015-09-15 2016-09-14 Treatment of diabetic peripheral neuropathy using placental cells

Publications (1)

Publication Number Publication Date
CO2018003759A2 true CO2018003759A2 (es) 2018-12-14

Family

ID=58289824

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0003759A CO2018003759A2 (es) 2015-09-15 2018-04-09 Tratamiento de la neuropatía periférica diabética usando células placentarias

Country Status (17)

Country Link
US (2) US20180264048A1 (es)
EP (2) EP3957315A1 (es)
JP (3) JP2018529683A (es)
KR (1) KR20180051631A (es)
CN (1) CN108367028A (es)
AU (1) AU2016323120A1 (es)
BR (1) BR112018005014B1 (es)
CA (1) CA2998759A1 (es)
CO (1) CO2018003759A2 (es)
EA (1) EA201890720A1 (es)
IL (2) IL281185B2 (es)
MX (1) MX2018003275A (es)
MY (1) MY203748A (es)
NZ (1) NZ740663A (es)
SG (1) SG10201912572VA (es)
WO (1) WO2017048741A1 (es)
ZA (1) ZA201801708B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4431647A1 (en) 2021-11-10 2024-09-18 Mitsubishi Chemical Corporation Carbon fibers, carbon fiber bundle, and production method for carbon fiber bundle

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
WO2000063263A1 (en) 1999-04-16 2000-10-26 Wm. Marsh Rice University Biodegradable poly(propylene fumarate) networks cross linked with poly(propylene fumarate)-diacrylate macromers
US6355699B1 (en) 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
AU2020902A (en) 2000-12-06 2002-06-18 Robert J Hariri Method of collecting placental stem cells background of the invention
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
KR100973615B1 (ko) 2001-02-14 2010-08-02 안트로제네시스 코포레이션 산후 포유류의 태반, 이의 용도 및 태반 줄기세포
EP2316918B1 (en) 2001-02-14 2015-07-01 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US20030187515A1 (en) 2002-03-26 2003-10-02 Hariri Robert J. Collagen biofabric and methods of preparing and using the collagen biofabric
US20040161419A1 (en) * 2002-04-19 2004-08-19 Strom Stephen C. Placental stem cells and uses thereof
US7255729B2 (en) 2003-05-30 2007-08-14 Noritake Co., Limited Porous cylindrical-body module, structure for supporting porous cylindrical bodies, and method for fastening a supporting member
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
AU2006332678B2 (en) 2005-12-29 2013-12-05 Celularity Inc. Placental stem cell populations
CA2633980A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Improved composition for collecting and preserving placental stem cells and methods of using the composition
US20090018151A1 (en) * 2007-02-23 2009-01-15 Ezekiel Fink Topical Treatment of Peripheral diabetic complications
CN107699541A (zh) * 2010-04-07 2018-02-16 人类起源公司 使用胎盘干细胞的血管生成
CN104220081A (zh) * 2011-06-01 2014-12-17 人类起源公司 利用胎盘干细胞治疗疼痛

Also Published As

Publication number Publication date
EP3349771A4 (en) 2019-04-24
NZ740663A (en) 2022-12-23
CN108367028A (zh) 2018-08-03
EP3957315A1 (en) 2022-02-23
JP2023171769A (ja) 2023-12-05
MX2018003275A (es) 2018-05-16
BR112018005014A2 (es) 2018-10-02
EP3349771A1 (en) 2018-07-25
CA2998759A1 (en) 2017-03-23
AU2016323120A1 (en) 2018-04-12
JP2021183635A (ja) 2021-12-02
IL258048A (en) 2018-05-31
US20180264048A1 (en) 2018-09-20
IL281185B1 (en) 2024-01-01
SG10201912572VA (en) 2020-02-27
IL281185A (en) 2021-04-29
ZA201801708B (en) 2019-01-30
BR112018005014B1 (pt) 2022-03-22
MY203748A (en) 2024-07-17
IL281185B2 (en) 2024-05-01
KR20180051631A (ko) 2018-05-16
JP2018529683A (ja) 2018-10-11
EA201890720A1 (ru) 2018-09-28
US20220072063A1 (en) 2022-03-10
WO2017048741A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
MX382337B (es) Terapia génica de globina y uso de la misma para el tratamiento de hemoglobinopatias.
WO2016070166A3 (en) Messenger una molecules and uses thereof
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
MX2023012263A (es) Mejora del efecto de celulas t dise?adas por car por medio de vacunacion con acido nucleico.
MX2016013963A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2018011012A (es) Formulaciones y dosis de uricasa pegilada.
PE20150200A1 (es) Formulacion de anticuerpos
MX2017008875A (es) Anticuerpos biespecificos contra cd3 y cd20.
MX372723B (es) Métodos para marcar una molécula deuterada o no deuterada y formulaciones farmacéuticas para tratamiento.
CL2017002031A1 (es) Formulación en polvo nasal para el tratamiento de hipoglicemia
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX2015015409A (es) Proceso para la preparacion de eritrocitos cargados con una o mas sustancias de interes farmaceutico y eritrocitos asi obtenidos.
CL2018000963A1 (es) Cosmética que tiene bacterias probióticas
UY36920A (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral
CO2017000056A2 (es) Moléculas que tienen cierta utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CL2018001104A1 (es) Composición para el cuidado de la piel y procedimiento asociado.
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
EA201390287A1 (ru) Теобромин в комбинации с отхаркивающим или муколитическим средствами для применения в терапии
MX395106B (es) Celulas t alogenicas específicas de wt1 y usos de las mismas.
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.